Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Opinion
Case: 24-1564 Document: 28 Page: 1 Filed: 08/20/2024
NOTE: This order is nonprecedential.
United States Court of Appeals for the Federal Circuit ______________________
REGENERON PHARMACEUTICALS, INC.,
Appellant v.
MYLAN PHARMACEUTICALS INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD.,
Appellees ______________________
2024-1564, 2024-1567 ______________________
Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2022- 01225, IPR2022-01226, IPR2023-00532, IPR2023-00533, and IPR2023-00566. ______________________ ON MOTION ______________________
ORDER
Upon consideration of Regeneron Pharmaceuticals, Inc.’s unopposed motion to voluntarily dismiss the above- captioned appeals pursuant to Federal Rule of Appellate Procedure 42, Case: 24-1564 Document: 28 Page: 2 Filed: 08/20/2024
2 REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC.
IT IS ORDERED THAT: (1) The motion is granted, and the appeals are dis- missed. (2) Each party shall bear its own costs for each appeal. FOR THE COURT
August 20, 2024
Date
ISSUED AS A MANDATE: August 20, 2024
Case-law data current through September 30, 2026. Source: CourtListener bulk data.